The company highlighted a series of strategic moves during the year, including the acquisition of WOKADINE, marking its entry into the Rs. 648 Cr Povidone Iodine market
Pharma major to engage with institutional investors through group meetings in Mumbai and Singapore during May 2026
Mumbai event on June 24–25 will spotlight real-world impact of pharmacovigilance beyond AI adoption
The biosimilars business generated Rs. 10,431 crore in FY26 revenue, up 16% year-on-year
FY26 revenue rises 17% to Rs. 5,453 crore as US generics business jumps 49% and adjusted EBITDA margin improves to 26% for the quarter
Fresenius Kabi's approved generic therapy addresses acute symptomatic hypocalcemia and targets a US market valued at nearly $71 million
The private funding rose 38% amid growing international collaborations and CDMO demand
Approval expands Lupin’s specialty portfolio in the US market for treatment of urea cycle disorders
Company plans to appeal against CGST order related to alleged inadmissible input tax credit claims
Keeps Halo Pharma to drive independent growth
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
